Collaboration Uses Next-Gen Sequencing for Biosafety Assessments - - BioPharm International

ADVERTISEMENT

Collaboration Uses Next-Gen Sequencing for Biosafety Assessments


Covance Inc. and Pathoquest have announced a collaboration to provide next-generation sequencing (NGS) based biosafety assessments to detect and identify viral contaminants within biologic compounds throughout the lifecycle of the product.

In a press statement the companies report that since viral contamination poses a significant potential safety risk to patients, regulatory agencies are increasingly focusing on the use of advanced analytical technologies like NGS for detection of viral contaminants.

The NGS solution offered by the companies overcomes the primary limitation of traditional approaches that only identify a predefined, short list of viruses and instead provides a universal test for identifying any virus in a single, analysis that minimizes false negatives, the companies report.

Covance and Pathoquest will provide clients with a range of options for adventitious virus identification, including a rapid detection protocol for the critical evaluation of major issues within production processes and an approach for development and characterization of cell banks and biological production systems.

Source: Covance Inc.

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here